Allergan PLC (NYSE:AGN) has been given a $294.00 price objective by research analysts at Bank of America Corp. in a report issued on Tuesday. The firm currently has a a “buy” rating on the stock. Bank of America Corp.’s target price would indicate a potential upside of 23.18% from the stock’s previous close.

A number of other equities analysts have also issued reports on the company. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Allergan PLC in a research report on Wednesday, July 6th. Leerink Swann upped their target price on Allergan PLC from $272.00 to $294.00 and gave the company an “outperform” rating in a research report on Wednesday, July 27th. JPMorgan Chase & Co. set a $325.00 target price on Allergan PLC and gave the company a “buy” rating in a research report on Friday, August 5th. Zacks Investment Research lowered Allergan PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Finally, Vetr raised Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $285.60 price target on the stock in a research report on Monday, August 1st. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $308.54.

Shares of Allergan PLC (NYSE:AGN) traded down 1.03% during midday trading on Tuesday, hitting $236.21. 2,424,302 shares of the company’s stock traded hands. Allergan PLC has a 52 week low of $195.50 and a 52 week high of $322.68. The company has a 50 day moving average of $245.54 and a 200 day moving average of $243.04. The stock has a market cap of $93.53 billion, a P/E ratio of 22.49 and a beta of 0.73.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/allergan-plc-agn-pt-set-at-294-00-by-bank-of-america-corp.html

Allergan PLC (NYSE:AGN) last announced its earnings results on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period in the prior year, the company posted $4.41 EPS. Allergan PLC’s quarterly revenue was up 1.0% on a year-over-year basis. On average, equities analysts forecast that Allergan PLC will post $14.01 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Barnett & Company Inc. bought a new position in Allergan PLC during the first quarter worth $111,000. Ropes Wealth Advisors LLC raised its position in Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock worth $133,000 after buying an additional 58 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management bought a new position in Allergan PLC during the second quarter worth $125,000. Trust Co. of Vermont raised its position in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock worth $126,000 after buying an additional 89 shares during the period. Finally, Integrated Investment Consultants LLC raised its position in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock worth $137,000 after buying an additional 154 shares during the period. Institutional investors and hedge funds own 85.19% of the company’s stock.

Allergan PLC Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.